<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01860287</url>
  </required_header>
  <id_info>
    <org_study_id>UCIRB-130197</org_study_id>
    <nct_id>NCT01860287</nct_id>
  </id_info>
  <brief_title>The Effects of Buprenorphine on Responses to Verbal Tasks</brief_title>
  <official_title>The Effects of Buprenorphine on Responses to Verbal Tasks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators will examine the effects of buprenorphine, as compared to
      placebo, upon physiological, subjective, and hormonal responses to a stressful speech task
      and a non-stressful control task in healthy adults. There is strong evidence in support of
      the role of endogenous opioids and opiates in mediating social behavior in humans and other
      animals, and particularly, in social distress. Recently it has been shown that buprenorphine,
      a partial mu-opioid agonist, reduces sensitivity to recognition of fearful facial expressions
      in humans. Here, the investigators propose to further explore the role of the opioid system
      in mediating stress responses in humans through the use of buprenorphine. The investigators
      hypothesize that buprenorphine with reduce both physiological and subjective measures of
      stress.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Effects as Assessed by Score on &quot;Feel Drug&quot;, &quot;Feel High&quot;, &quot;Like Drug&quot;, and &quot;Want More&quot; Subscales of the Drug Effects Questionnaire Subjective Responses to Stress With and Without Buprenorphine</measure>
    <time_frame>End of study - (Pre-administration of drug or placebo (Time 0), and approx 210 minutes after drug/placebo admin), End of study (210 min) shown</time_frame>
    <description>The Drug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: &quot;Feel Drug&quot;, &quot;Feel High&quot;, and &quot;Want More&quot;. The &quot;Feel Drug&quot;, &quot;Feel High&quot;, &quot;Like Drug&quot;, and &quot;Want More&quot; subscales are reported. All subscales are scored on a visual analogue scale (scroll bar on computer screen) ranging from 0 -100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Basic Science</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy volunteers receive placebo during session (within-subjects design).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>buprenorphine (0.2 mg) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers receive buprenorphine (0.2 mg) during session (within-subjects design).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>buprenorphine (0.4 mg) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers receive buprenorphine (0.4 mg) during session (within-subjects design).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine 0.2 MG Sublingual Tablet</intervention_name>
    <description>This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.2)</description>
    <arm_group_label>buprenorphine (0.2 mg) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive a placebo</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine 0.4 MG Sublingual Tablet</intervention_name>
    <description>This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.4)</description>
    <arm_group_label>buprenorphine (0.4 mg) group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women

          -  ages 18-40 years

          -  high school education

          -  fluent in English

        Exclusion Criteria:

          -  history of adverse drug reactions

          -  taking oral contraceptives or planning to become pregnant

          -  taking any medications

          -  smokers

          -  night shift workers

          -  drink more than 4 alcoholic or caffeinated drinks per day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harriet de Wit, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerome Jaffe, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 6, 2013</study_first_submitted>
  <study_first_submitted_qc>May 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2013</study_first_posted>
  <results_first_submitted>April 4, 2019</results_first_submitted>
  <results_first_submitted_qc>May 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 1, 2019</results_first_posted>
  <last_update_submitted>May 30, 2019</last_update_submitted>
  <last_update_submitted_qc>May 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>opioid</keyword>
  <keyword>subjective</keyword>
  <keyword>stress</keyword>
  <keyword>buprenorphine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Group</title>
          <description>Healthy volunteers receive placebo</description>
        </group>
        <group group_id="P2">
          <title>0.2 Buprenorphine</title>
          <description>Healthy volunteers will receive 0.2 mg of buprenorphine</description>
        </group>
        <group group_id="P3">
          <title>0.4 mg Buprenorphine</title>
          <description>Healthy volunteers will receive 0.4 mg of buprenorphine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Group</title>
          <description>Healthy volunteers receive placebo during session (within-subjects design).
Placebo: This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive a placebo</description>
        </group>
        <group group_id="B2">
          <title>Buprenorphine (0.2 mg) Group</title>
          <description>Healthy volunteers receive buprenorphine (0.2 mg) during session (within-subjects design).
Buprenorphine 0.2 MG Sublingual Tablet: This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.2)</description>
        </group>
        <group group_id="B3">
          <title>Buprenorphine (0.4 mg) Group</title>
          <description>Healthy volunteers receive buprenorphine (0.4 mg) during session (within-subjects design).
Buprenorphine 0.4 MG Sublingual Tablet: This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.4)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjective Effects as Assessed by Score on &quot;Feel Drug&quot;, &quot;Feel High&quot;, &quot;Like Drug&quot;, and &quot;Want More&quot; Subscales of the Drug Effects Questionnaire Subjective Responses to Stress With and Without Buprenorphine</title>
        <description>The Drug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: &quot;Feel Drug&quot;, &quot;Feel High&quot;, and &quot;Want More&quot;. The &quot;Feel Drug&quot;, &quot;Feel High&quot;, &quot;Like Drug&quot;, and &quot;Want More&quot; subscales are reported. All subscales are scored on a visual analogue scale (scroll bar on computer screen) ranging from 0 -100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome.</description>
        <time_frame>End of study - (Pre-administration of drug or placebo (Time 0), and approx 210 minutes after drug/placebo admin), End of study (210 min) shown</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>Healthy volunteers receive placebo</description>
          </group>
          <group group_id="O2">
            <title>0.2 Buprenorphine</title>
            <description>Healthy volunteers will receive 0.2 mg of buprenorphine</description>
          </group>
          <group group_id="O3">
            <title>0.4 mg Buprenorphine</title>
            <description>Healthy volunteers will receive 0.4 mg of buprenorphine</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Effects as Assessed by Score on &quot;Feel Drug&quot;, &quot;Feel High&quot;, &quot;Like Drug&quot;, and &quot;Want More&quot; Subscales of the Drug Effects Questionnaire Subjective Responses to Stress With and Without Buprenorphine</title>
          <description>The Drug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: &quot;Feel Drug&quot;, &quot;Feel High&quot;, and &quot;Want More&quot;. The &quot;Feel Drug&quot;, &quot;Feel High&quot;, &quot;Like Drug&quot;, and &quot;Want More&quot; subscales are reported. All subscales are scored on a visual analogue scale (scroll bar on computer screen) ranging from 0 -100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Feel Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.57" spread="2.1"/>
                    <measurement group_id="O2" value="36.57" spread="4.5"/>
                    <measurement group_id="O3" value="59.89" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Like Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="1.2"/>
                    <measurement group_id="O2" value="43.27" spread="3.6"/>
                    <measurement group_id="O3" value="56.25" spread="4.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feel High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="1.5"/>
                    <measurement group_id="O2" value="27.27" spread="2.5"/>
                    <measurement group_id="O3" value="41.69" spread="3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Want More</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.27" spread="1.3"/>
                    <measurement group_id="O2" value="12.47" spread="1.9"/>
                    <measurement group_id="O3" value="21.57" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 days for each intervention</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Group</title>
          <description>Healthy volunteers receive placebo</description>
        </group>
        <group group_id="E2">
          <title>0.2 Buprenorphine</title>
          <description>Healthy volunteers will receive 0.2 mg of buprenorphine</description>
        </group>
        <group group_id="E3">
          <title>0.4 mg Buprenorphine</title>
          <description>Healthy volunteers will receive 0.4 mg of buprenorphine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Harriet de Wit</name_or_title>
      <organization>University of Chicago</organization>
      <phone>7737023560</phone>
      <email>dewitlab@yoda.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

